A Phase 2b, Study of Linsitinib in Subjects With Active, Moderate to Severe Thyroid Eye Disease (TED)
Status:
Not yet recruiting
Trial end date:
2025-06-13
Target enrollment:
Participant gender:
Summary
The overall objective is to study the safety, pharmacokinetics and efficacy of linsitinib (a
small molecule IGF-1R inhibitor) administered orally twice daily (BID) vs. placebo, at 24
weeks in the treatment of subjects with active, moderate to severe thyroid eye disease (TED).